NCT06787183

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

A Phase II Multicenter Clinical Trail of Efficacy and Safety of Short Course Radiotherapy Combined With CAPOX and PD-1/CTLA-4 Bispecific Antibody QL1706 in Patients With Liver Metastases From Rectal Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.

Conditions

• Locally Advanced Rectal Cancer With Liver Metastases

Interventions

Type	Name	Description
RADIATION	Short course radiotherapy	CTV 25Gy/5Fx.
DRUG	Capecitabine	1000mg/m2, d1-14，bid, q3w, 2 cycles.
DRUG	Oxaliplatin	130mg/m2, d1, q3w, 2 cycles
DRUG	QL1706	5.0 mg/kg, q3w

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-12-01
• Completion: 2029-12-01
• First posted: 2025-01-22
• Last updated: 2026-03-03

Locations

2 sites across 1 country: China